前沿生物(688221.SH)：2025年三季报净利润为-1.60亿元

Core Insights - The company reported total operating revenue of 103 million, ranking 151 among disclosed peers [1] - The net profit attributable to shareholders was -160 million, ranking 148 among disclosed peers [1] - The net cash flow from operating activities was -152 million, ranking 145 among disclosed peers, a decrease of 17.86 million compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 40.06%, ranking 103 among disclosed peers, an increase of 2.82 percentage points from the previous quarter [3] - The latest gross profit margin is 34.84%, ranking 109 among disclosed peers [3] - The latest return on equity (ROE) is -16.28%, ranking 148 among disclosed peers [3] - The diluted earnings per share is -0.43 yuan, ranking 147 among disclosed peers [3] - The latest total asset turnover ratio is 0.06 times, ranking 152 among disclosed peers [3] - The latest inventory turnover ratio is 1.50 times, ranking 88 among disclosed peers [3] Shareholder Structure - The number of shareholders is 16,400, with the top ten shareholders holding 178 million shares, accounting for 47.46% of the total share capital [3] - The largest shareholder is Jianmu Pharmaceutical Co., Ltd., holding 18.86% [3] - Other notable shareholders include LU RONGJIAN (5.80%), WANG CHANGJIN (5.62%), and Nanjing Jianmu Business Consulting Partnership (4.59%) [3]